Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Neoplasm
51%
Pancreas Cancer
48%
Pancreaticoduodenectomy
46%
Pancreatectomy
42%
Overall Survival
30%
Surgery
28%
Neoadjuvant Therapy
26%
Malignant Neoplasm
24%
Intraductal Papillary Mucinous Tumor
12%
Odds Ratio
11%
Pancreas Islet Cell Tumor
10%
Pancreas Fistula
10%
Adenocarcinoma
9%
Chemoradiotherapy
9%
Diseases
9%
Lymph Node
9%
Gemcitabine
8%
Clinical Pathway
8%
Distal Pancreatectomy
8%
CA 19-9 Antigen
8%
Paclitaxel
8%
Cancer Cell
8%
Xenograft
7%
Recurrent Disease
7%
Hazard Ratio
7%
Tumor Xenograft
7%
Pancreatic Ductal Adenocarcinoma
6%
Radiation Therapy
6%
Health Care Cost
6%
Biological Marker
5%
Preoperative Chemotherapy
5%
Recurrence Free Survival
5%
Transcriptomics
5%
Hepatic Portal Vein
5%
Keyphrases
Pancreatic Ductal Adenocarcinoma
57%
Neoadjuvant Therapy
29%
Pancreatectomy
27%
Pancreaticoduodenectomy
27%
Pancreatic Adenocarcinoma
25%
Pancreatic Cancer
23%
Preoperative Therapy
23%
Overall Survival
21%
Tumor
19%
Carbohydrate Antigen 19-9 (CA19-9)
13%
Risk Stratification
10%
Resection
10%
Pathologic
8%
Patient-derived
8%
Chemotherapy
8%
Clinical Pathway
8%
Pancreas
8%
Pancreatic Tumor
8%
Surgery First
8%
Intraductal Papillary mucinous Neoplasm
8%
Postoperative Pancreatic Fistula
7%
Hazard Ratio
7%
Distal Pancreatectomy
6%
Engraftment
6%
Confidence Interval
6%
Preoperative Chemotherapy
6%
Metastatic Pancreatic Ductal Adenocarcinoma
6%
Chemoradiation
6%
Resectable Pancreatic Cancer
6%
Cancer Xenograft
6%
Microenvironment
6%
Pancreatic Fistula
5%
Gemcitabine
5%
High Risk
5%
Single Institution
5%